Advertisement.

IFRX Projected Dividend Yield

Ord/InflaRx NV ( NASDAQ : IFRX )

InflaRx is a clinical-stage biopharmaceutical company focused on applying its anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. C5a is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. Co.'s primary product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in various clinical settings. Co. develops vilobelimab for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease.

20 YEAR PERFORMANCE RESULTS

IFRX Dividend History Detail
IFRX Dividend News
IFRX Competitors News

# of Shares: 0

Closing Price: 2.36

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000